Log In
Print
BCIQ
Print
Print this Print this
 

ACY-738

  Manage Alerts
Collapse Summary General Information
Company Acetylon Pharmaceuticals Inc.
DescriptionSelective histone deacetylase 1 (HDAC1) and histone deacetylase 2 (HDAC2) inhibitor
Molecular Target Histone deacetylase 1 (HDAC1) ; Histone deacetylase 2 (HDAC2)
Mechanism of ActionHistone deacetylase (HDAC) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard Indication Neurology (unspecified)
Indication DetailsTreat neurodegeneration
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1,700.0M

$100.0M

$1,100.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today